HomePress ReleasesMilliporeSigma Supports Eijkman Institute to Expedite Covid-19 Vaccine Development Research

MilliporeSigma Supports Eijkman Institute to Expedite Covid-19 Vaccine Development Research

News Release

  • Eijkman Institute for Molecular Biology developing Covid-19 vaccine based on local strain virus strain
  • Institute to receive research instruments and materials to advance production

Jakarta, Indonesia, September 3, 2020 — MilliporeSigma, a leading science and technology company, today announced the donation of research instruments and materials worth IDR 1.2 billion (€ 74,000) to support the efforts of Eijkman Institute for Molecular Biology, Indonesia, in its efforts to accelerate vaccine development research. The institute is developing a Covid-19 vaccine based on a local virus strain, in collaboration with several local research institutions.

“MilliporeSigma supplies critical products and services and provides solutions for scientists to identify and characterize viruses and develop vaccines and therapies – work that is especially important as vaccine developers race to fight Covid-19,” said Christopher Thomas, president director at MilliporeSigma in Indonesia. “Eijkman Institute’s work is promising and we are committed to supporting them.”

MilliporeSigma is donating reagents and consumables to make viral transport medium, which are tubes that store patients’ swab test samples, allowing them to be safely transported from swab sampling locations (i.e., clinics, hospitals, health centers) to testing labs. The company is also donating RiOs™ Essential water purification systems, which produce high-quality type-3 pure water by integrating pre-treatment and high-performance reverse osmosis membranes.

"The utmost priority in combating Covid-19 is accelerating the discovery of Covid-19 vaccine to protect people and breaking the chain of infection in Indonesia,” said Professor Amin Soebandrio, chairman of Eijkman Institute for Molecular Biology. “Prevention is certainly better than cure. Global partners and qualified state-of-the-art research instruments will greatly help in expediting this vaccine research. We are grateful for MilliporeSigma’s support in donating instruments and materials to help us in developing Indonesia’s Covid-19 vaccine."

Eijkman Institute’s research has progressed to the generation of sub-unit protein as the chosen platform. In general, vaccine manufacturing can take years to finish, but the institute is racing to generate the vaccine seed in only a year. It is estimated that the vaccine will be made available for further processes including clinical trials in Indonesia by early 2021.

About the Life Science business of Merck KGaA, Darmstadt, Germany 

The Life Science business of Merck KGaA, Darmstadt, Germany, which operates as MilliporeSigma in the U.S. and Canada, has more than 23,000 employees and 59 manufacturing sites worldwide, with a portfolio of more than 300,000 products focused on scientific discovery, biomanufacturing and testing services. Merck KGaA, Darmstadt, Germany, a leading science and technology company, operates across healthcare, life science and electronics.

Around 58,000 employees work to make a positive difference to millions of people’s lives every day by creating more joyful and sustainable ways to live. From advancing gene-editing technologies and discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2020, Merck KGaA, Darmstadt, Germany generated sales of € 17.5 billion in 66 countries.

The company holds the global rights to the name and trademark “Merck” internationally. The only exceptions are the United States and Canada, where the business sectors of Merck KGaA, Darmstadt, Germany operate as EMD Serono in healthcare, MilliporeSigma in life science, and EMD Electronics. Since its founding 1668, scientific exploration and responsible entrepreneurship have been key to the company’s technological and scientific advances. To this day, the founding family remains the majority owner of the publicly listed company. For more information about Merck KGaA, Darmstadt, Germany, visit

All Merck KGaA, Darmstadt, Germany news releases are distributed by email at the same time they become available on the EMD Group website. In case you are a resident of the U.S. or Canada please go to to register again for your online subscription of this service as our newly introduced geo-targeting requires new links in the email. You may later change your selection or discontinue this service. 

Follow MilliporeSigma on Twitter @MilliporeSigma, on Facebook @MilliporeSigma and on LinkedIn.

Phone: +1 978-436-1725

Latest Press Releases

Sign In To Continue

To continue reading please sign in or create an account.

Don't Have An Account?